經月經檢測市場規模、佔有率及成長分析（依產品類型、治療方法、最終用戶及地區分類）－2026-2033年產業預測

全球月經疼痛測試市場規模預計在 2024 年達到 38.9 億美元，從 2025 年的 42.1 億美元成長到 2033 年的 78.4 億美元，在預測期（2026-2033 年）內複合年成長率為 8.1%。

全球月經檢測市場正經歷顯著成長，這主要得益於月經盛行率的上升、人們對月經健康意識的增強以及診斷技術的進步。隨著月經患者人數的增加，對臨床評估和檢測服務的需求也隨之激增。政府推出的支持性政策，例如資助月經健康研究和推廣全國篩檢措施，進一步提高了月經檢測的可及性。生殖健康診所的增加以及人們對不孕症治療日益成長的興趣，也拓展了檢測機會。人工智慧、機器學習和物聯網等創新技術透過對症狀和模式進行數據分析，正在變革診斷方式；而擴增實境（AR）和虛擬實境（VR）技術則在提升臨床醫生的培訓水準。科技與意識的融合正在塑造月經檢測的未來。

全球月經檢測市場促進因素

隨著原發性和續發性月經的盛行率不斷上升，越來越多的女性主動尋求醫療協助以應對慢性或嚴重的月經，這推動了對明確診斷方案的需求。這種日益增強的意識進一步強化了月經檢測的必要性。此外，致力於促進女性健康的政府和非政府組織的活動也進一步提升了月經紊亂疾病篩檢的重要性。因此，健康意識的提高和教育活動的開展所產生的協同效應正在推動全球月經檢測市場的擴張。

限制全球月經檢測市場的因素

全球月經檢測市場面臨許多挑戰，這些挑戰源自於將月經視為恥辱的文化觀念。這種污名不僅阻礙了公開討論，也限制了女性獲得必要的月經健康服務。在較保守的社區，女性往往面臨許多障礙，難以將自身健康放在第一位，尤其是在疼痛症狀常被輕描淡寫的情況下。此外，即使患者願意分享自身經歷，根深蒂固的性別偏見也可能阻礙醫療服務提供者進行更深入的調查，從而影響月經的診斷和治療。這些以及其他社會因素都對市場發展構成限制。

全球月經檢測市場趨勢

全球月經檢測市場正呈現顯著成長趨勢，這主要得益於人們對月經健康的認知不斷提高，以及相關討論日趨規範化。政府和非營利組織主導的教育活動有效打破了與月經疼痛相關的污名，鼓勵更多女性尋求月經檢測及相關醫療服務。這種日益成長的認知推動了對先進檢測解決方案的需求，例如荷爾蒙水平檢測、超音波和創新的深度學習成像技術，這些解決方案能夠提供個人化的評估。隨著女性尋求更全面的治療方案，市場呈現成長態勢，這也反映了更廣泛的健康趨勢，即女性生殖健康和福祉日益受到重視。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

全球月經檢測市場規模（依產品類型及複合年成長率分類）（2026-2033 年）

• 原發性經痛檢查
• 次發性月經

全球月經檢測市場規模（依治療方法和複合年成長率分類）（2026-2033 年）

• 止痛藥
• 荷爾蒙療法
• 外科手術

全球月經檢測市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 研究中心

全球月經檢測市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.
• Bayer AG
• Johnson & Johnson Services, Inc.
• Quin
• Abbott Laboratories
• Merck & Co., Inc.
• Global Pharma plc
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Proteomics Inc.
• Boehringer Ingelheim International GmbH
• Ferring Pharmaceuticals

結論與建議

Global Dysmenorrhea Testing Market size was valued at USD 3.89 Billion in 2024 and is poised to grow from USD 4.21 Billion in 2025 to USD 7.84 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global dysmenorrhea testing market is experiencing significant growth driven by the increasing prevalence of dysmenorrhea, heightened awareness surrounding menstrual health, and advancements in diagnostic technologies. As more individuals face menstrual pain, there is a surge in demand for clinical evaluations and testing services. Supportive government policies promoting funding for menstrual health research and national screening initiatives have further improved access to dysmenorrhea testing. The rise of reproductive health clinics and awareness around fertility has amplified testing opportunities. Innovations such as artificial intelligence, machine learning, and IoT are transforming diagnostics by enabling data analysis of symptoms and patterns, while augmented and virtual reality are enhancing clinician training. This convergence of technology and awareness is shaping the future landscape of dysmenorrhea testing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dysmenorrhea Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dysmenorrhea Testing Market Segments Analysis

Global Dysmenorrhea Testing Market is segmented by Product Type, Type of Treatment, End User and region. Based on Product Type, the market is segmented into Primary Dysmenorrhea Testing and Secondary Dysmenorrhea Testing. Based on Type of Treatment, the market is segmented into Pain Relievers, Hormonal Therapy and Surgery. Based on End User, the market is segmented into Hospitals and Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dysmenorrhea Testing Market

The rising prevalence of both primary and secondary dysmenorrhea has led to an increased demand for clear diagnostic solutions, as more women actively seek medical assistance for chronic or intense menstrual pain. This growing awareness has heightened the necessity for dysmenorrhea testing. Additionally, the efforts of governments and non-governmental organizations promoting women's health have further stimulated the importance of medical screenings for menstrual disorders. As a result, the combination of heightened health awareness and advocacy initiatives is driving the expansion of the Global Dysmenorrhea Testing market.

Restraints in the Global Dysmenorrhea Testing Market

The Global Dysmenorrhea Testing market faces significant challenges rooted in cultural perceptions surrounding menstruation, which often view it as a source of shame. This stigma not only hampers open discussion but also restricts access to essential menstrual health services. In more conservative communities, women frequently encounter barriers that prevent them from prioritizing their health, particularly when experiencing painful symptoms that are commonly dismissed. Furthermore, even when patients communicate their experiences, healthcare providers may neglect to pursue further investigation due to inherent gender biases, ultimately impacting diagnosis and treatment for dysmenorrhea. Such societal factors contribute to the overall restraints in the market.

Market Trends of the Global Dysmenorrhea Testing Market

The Global Dysmenorrhea Testing market is experiencing a significant upward trend driven by increasing awareness and the normalization of menstrual health discussions. Educational initiatives spearheaded by governments and nonprofit organizations are effectively breaking stigmas associated with menstrual pain, prompting more women to pursue dysmenorrhea testing and related healthcare services. This heightened awareness is fueling demand for advanced testing solutions, including hormonal profiling, ultrasounds, and innovative deep learning imaging techniques, which allow for personalized assessments. As women seek informed care options, the market is poised for growth, reflecting broader health trends focused on women's reproductive health and well-being.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Dysmenorrhea Testing Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Primary Dysmenorrhea Testing
• Secondary Dysmenorrhea Testing

Global Dysmenorrhea Testing Market Size by Type of Treatment & CAGR (2026-2033)

• Market Overview
• Market Overview
• Pain Relievers
• Hormonal Therapy
• Surgery

Global Dysmenorrhea Testing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Research Centers

Global Dysmenorrhea Testing Market Size & CAGR (2026-2033)

• North America (Product Type, Type of Treatment, End User)
  • US
  • Canada
• Europe (Product Type, Type of Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Type of Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Type of Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Type of Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Pharma plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteomics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations